Evidence map›Paper›PMID 39668284›Full record

ArticleInternational journal of hematology2025

Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan.

Hirokazu Kashiwagi, Isao Miura, Naohiko Terasawa, Ken-Ichi Iwayama, Yuka Furukawa, Makoto Kanenishi

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Hirokazu KashiwagiDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Postal Address: 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. kashi@hp-blood.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-4814-8667
Isao MiuraMedical Department, Kissei Pharmaceutical Co., Ltd, Tokyo, Japan.
Naohiko TerasawaMedical Department, Kissei Pharmaceutical Co., Ltd, Tokyo, Japan.
Ken-Ichi IwayamaMedical Department, Kissei Pharmaceutical Co., Ltd, Tokyo, Japan.
Yuka FurukawaRWE Group Clinical Research Department, Ark Medical Solutions Inc, Tokyo, Japan.
Makoto KanenishiRWE Group Clinical Research Department, Ark Medical Solutions Inc, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent trends in the treatment of primary immune thrombocytopenia (ITP) were investigated using a claims database that included data from 16,161 Japanese patients with ITP collected from April 2014 to August 2022. Of the 4144 adult patients analyzed, 1276 received corticosteroids. The mean and median durations of corticosteroid use were 115.31 and 41 days, respectively. The time to withdrawal of corticosteroids was significantly shorter in 2020 to 2021 than in 2015 to 2019. Additionally, the number of prescriptions for thrombopoietin receptor agonists increased from 2015 to 2021 and exceeded that of corticosteroids in 2021. While these results suggest a trend towards reduction in corticosteroid use in real-world settings in Japan, 12.00% of patients received a corticosteroid dose of ≥ 10 mg/day at Week 12. Furthermore, 23.05% of patients continued to receive corticosteroids at Week 24, indicating that some patients were still receiving long-term corticosteroid treatment. The risk of adverse outcomes was significantly associated with corticosteroid use. In conclusion, new treatment options may lead to more sophisticated ITP management with less corticosteroid use, although further research and reconsideration of clinical practice guidelines is needed.

Indexed as

Adrenal Cortex HormonesPurpura, Thrombocytopenic, IdiopathicAdultAgedAged, 80 and overDatabases, FactualFemaleHumansJapanMaleMiddle AgedReceptors, ThrombopoietinYoung AdultAdrenal Cortex HormonesReceptors, ThrombopoietinAdverse effectCorticosteroidsDatabase studyImmune thrombocytopeniaTreatment pattern

Identifiers

PMID39668284
PMCPMC11861122

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.